NCT02103439 - An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

June 6, 2013

Primary Completion Date

August 26, 2015

Study Completion Date

August 26, 2015

Conditions

HepatitisHepatitis CHepatitis C/ Human Immunodeficiency Virus Coinfection

Interventions

DRUG

Algeron

1.5 µg/kg of body weight subcutaneously, once a week

DRUG

PegIntron

1.5 µg/kg of body weight subcutaneously, once a week

Trial Locations (6)

190103

State Healthcare Institution Center for the Prevention and Control of AIDS and infectious diseases of the city, St.Petersburg CityHealth Department, Saint Petersburg

400040

"State Healthcare Institution Volgograd Regional Center for the Prevention and Control of AIDS and infectious diseases", Volgograd

410012

State Budgetary Higher Vocational Education Institution V.I. Razumovsky Saratov State University of medicine, Saratov

420097

State Public Healthcare Institution National Center for the Prevention and Control of AIDS and other infectious diseases of the Ministry of Health of the Republic of Tatarstan, Kazan'

603005

"State Institution of Nizhny Novgorod region Regional Center for Prevention and Control of AIDS and other infectious diseases", Nizhny Novgorod

690002

State Budgetary Higher Vocational Education Institution Pacific State Medical University, Ministry of Health of the Russian Federation, Vladivostok